Jennifer Taubert Sells 56,471 Shares of Johnson & Johnson (NYSE:JNJ) Stock

Key Points

• Jennifer Taubert, EVP of Johnson & Johnson, sold 56,471 shares of the company’s stock on September 4th for a total of roughly $10 million, reducing their ownership by 24.08%.
• As of the report, Johnson & Johnson's stock is trading at $178.20 with a market cap of $429.15 billion and a PE ratio of 19.06.
• The company announced a quarterly dividend of $1.30, which translates to an annualized dividend yield of 2.9%, with plans to pay this dividend on September 9th.

Johnson & Johnson (NYSE:JNJ - Get Free Report) EVP Jennifer Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Johnson & Johnson Stock Performance

Shares of JNJ stock traded down $0.57 during trading on Friday, hitting $178.20. The company's stock had a trading volume of 9,733,095 shares, compared to its average volume of 8,970,201. The company has a market cap of $429.15 billion, a PE ratio of 19.06, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The business has a fifty day moving average of $168.06 and a 200-day moving average of $160.60. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the company earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. UBS Group boosted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Morgan Stanley increased their target price on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Finally, Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $176.29.

Institutional Trading of Johnson & Johnson

Several large investors have recently bought and sold shares of the company. Evolution Wealth Management Inc. bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth approximately $27,000. Semmax Financial Advisors Inc. boosted its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after buying an additional 72 shares during the period. GFG Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter worth $35,000. Highline Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after purchasing an additional 86 shares during the last quarter. Finally, Stone House Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 1st quarter valued at about $47,000. 69.55% of the stock is owned by institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.